markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Copart, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Candel Therapeutics
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Copart, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Candel Therapeutics appears in 1 tracked Finance story from February 20, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 75 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Candel Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.